Brokers Issue Forecasts for Egalet Corporation’s FY2017 Earnings (EGLT)
Egalet Corporation (NASDAQ:EGLT) – Stock analysts at Gabelli lifted their FY2017 earnings per share estimates for shares of Egalet Corporation in a research report issued to clients and investors on Thursday. Gabelli analyst K. Kedra now forecasts that the specialty pharmaceutical company will post earnings per share of ($2.55) for the year, up from their previous estimate of ($2.60). Gabelli currently has a “Hold” rating on the stock. Gabelli also issued estimates for Egalet Corporation’s FY2018 earnings at ($1.30) EPS, FY2019 earnings at ($1.00) EPS, FY2020 earnings at ($0.85) EPS and FY2021 earnings at ($0.80) EPS.
COPYRIGHT VIOLATION WARNING: “Brokers Issue Forecasts for Egalet Corporation’s FY2017 Earnings (EGLT)” was posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.watchlistnews.com/brokers-issue-forecasts-for-egalet-corporations-fy2017-earnings-eglt/1699136.html.
Several other analysts also recently weighed in on the company. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Egalet Corporation in a research note on Saturday, August 26th. Guggenheim set a $7.00 price target on Egalet Corporation and gave the company a “buy” rating in a research report on Monday, August 14th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $6.00 target price (down from $14.00) on shares of Egalet Corporation in a report on Thursday, August 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. Egalet Corporation currently has a consensus rating of “Buy” and a consensus price target of $7.10.
Shares of Egalet Corporation (NASDAQ:EGLT) opened at $0.86 on Monday. The company has a debt-to-equity ratio of -3.43, a current ratio of 2.73 and a quick ratio of 2.68. Egalet Corporation has a 12 month low of $0.85 and a 12 month high of $10.00.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. GMT Capital Corp bought a new stake in shares of Egalet Corporation in the 2nd quarter valued at approximately $1,281,000. NJ State Employees Deferred Compensation Plan acquired a new position in shares of Egalet Corporation in the 3rd quarter worth approximately $435,000. HighTower Advisors LLC boosted its holdings in shares of Egalet Corporation by 0.9% in the 2nd quarter. HighTower Advisors LLC now owns 268,644 shares of the specialty pharmaceutical company’s stock worth $636,000 after acquiring an additional 2,408 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Egalet Corporation by 515.7% in the 2nd quarter. Goldman Sachs Group Inc. now owns 123,454 shares of the specialty pharmaceutical company’s stock worth $293,000 after acquiring an additional 103,402 shares in the last quarter. Finally, New Jersey Better Educational Savings Trust boosted its holdings in shares of Egalet Corporation by 4.0% in the 2nd quarter. New Jersey Better Educational Savings Trust now owns 104,000 shares of the specialty pharmaceutical company’s stock worth $246,000 after acquiring an additional 4,000 shares in the last quarter. Hedge funds and other institutional investors own 33.39% of the company’s stock.
About Egalet Corporation
Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.
Receive News & Ratings for Egalet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.